Searched for
IPCA LABORATORIES STOCKS
PL Capital cuts Nifty target to 26,449, lists 16 high conviction stock picksAmidst global market turmoil from the Iran-US war and El Nino, PL Capital lowered its Nifty 50 target to 26,449. The brokerage anticipates ...- Ipca Laboratories among 5 stocks showing bullish RSI upswingFive Nifty500 stocks, including Leela Palaces, Eris Lifesciences, Indian Bank, Mankind Pharma, and Ipca Laboratories, showed bullish moment...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Ahead of Market: 10 things that will decide stock market action on WednesdayDomestic equities closed marginally lower due to weakness in financial and consumer shares, despite gains in IT stocks. Analysts suggest th...
- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- Ahead of Market: 10 things that will decide stock market action on TuesdayIndian indices were subdued with Nifty up 0.03% and Sensex down 0.10%. High volatility (VIX at 19.63) and bearish momentum indicators sugge...
- Gland Pharma,6 stocks hit 52-week highs, rally up to 20% in a monthDespite a marginal rise in the Sensex, seven BSE 500 stocks touched fresh 52-week highs, signalling strong bullish momentum. Gland Pharma, ...
- Buy Ipca Laboratories, target price Rs 1,980: Motilal Oswal Financial ServicesMotilal Oswal Financial Services recommends buying Ipca Laboratories with a target price of Rs 1980. The company reported strong quarterly ...
- Reduce Ipca Laboratories, target price Rs 1150: Prabhudas LilladherIpca Laboratories Ltd., incorporated in the year 1949, is a Mid Cap company (having a market cap of Rs 31697.80 Crore) operating in Pharmac...
- Stock Radar: This pharma stock is likely to top Rs 1000 levels in 1-2 months; time to buy?The stock rose from Rs 731 on 20 June to Rs 913 recorded on 20 September, which translates into an upside of 24% in 3 months. It hit a fres...
- Buy Ipca Laboratories, target price Rs 970: Nagaraj ShettiIpca Laboratories, incorporated in the year 1949, is a Mid Cap company (having a market cap of Rs 23532.33 Crore) operating in Pharmaceutic...
- Hold Ipca Laboratories, target price Rs 790: Sharekhan by BNP ParibasIpca Laboratories, incorporated in the year 1949, is a Mid Cap company (having a market cap of Rs 17596.92 Crore) operating in Pharmaceutic...
- Buy Ipca Laboratories, target price Rs 940: ICICI DirectIpca Laboratories, incorporated in the year 1949, is a Mid Cap company (having a market cap of Rs 20933.14 Crore) operating in Pharmaceutic...
- Buy Ipca Laboratories, target price Rs 1115: JM FinancialJM Financial adjusts its earnings by 3-5% to factor a gradual GM improvement.
- Hold Ipca Laboratories, target price Rs 909: Sharekhan by BNP ParibasIpca Laboratories, incorporated in the year 1949, is a Mid Cap company (having a market cap of Rs 20944.55 Crore) operating in Pharmaceutic...
- Add Ipca Laboratories, target price Rs 893: Choice Equity BrokingChoice Broking values the stock based on Sep-24E EPS to arrive at a target price of Rs 893 (valuing at 25x) and improve its rating from neu...
- Buy Ipca Laboratories, target price Rs 1010: JM FinancialIpca Laboratories, incorporated in the year 1949, is a Mid Cap company (having a market cap of Rs 20911.57 Crore) operating in Pharmaceutic...
- Hold Ipca Laboratories, target price Rs 865: Prabhudas LilladherAt CMP, the stock is trading at 23x FY25E factoring in near term recovery.
- Ipca Labs Q2 results: Net profit declines 6% to Rs 250 croreThe board has "approved subdivision of every 1 equity share of the nominal/face value of Rs 2/ each into 2 equity shares of the nominal/fac...
Load More
